J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

Nicole DeFeudis

Editor

Putting a damper on a years-long kinship, J&J says it’s partly backing out of two license agreements for Alkermes’ nanoparticle technology, which the pharma giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

J&J tries to back out of nanopar­ti­cle li­cense agree­ment — but Alk­er­mes says 'not so fast'

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'